Spinal Cord Seizures Symptoms: Key Indicators and Root Causes

Spinal cord seizures are brief, involuntary episodes of intense muscle stiffening and abnormal sensation that originate not in the brain but in the spinal cord itself. They typically last less than two minutes, produce no loss of consciousness, and show no abnormality on a standard brain-wave recording, which is why they are frequently misdiagnosed or overlooked entirely.¹ Because their symptoms can mimic epileptic seizures, movement disorders, or ordinary muscle spasms, recognizing the pattern and understanding the root causes matters for getting the right treatment.

What Spinal Cord Seizures Actually Feel Like

The hallmark symptom is a sudden tonic spasm, a sustained, often forceful contraction that locks one or more limbs into a rigid posture. Unlike a typical muscle cramp that builds gradually, these episodes strike abruptly and may affect one side of the body, both legs, or all four limbs depending on where the spinal cord is damaged. The spasm is frequently accompanied by painful dysesthesias: burning, tingling, electric-shock-like sensations, or a deep aching pain that radiates along the trunk or limbs.¹ These sensory disturbances often follow a dermatomal pattern, meaning the pain or tingling traces a band around the torso or down a limb in a way that maps to a specific spinal cord level.

Episodes are fleeting. Most last from a few seconds to about two minutes, though they can recur many times a day. Some people notice that certain triggers set them off: a light touch, a sudden movement, a change in position, hyperventilation, or even emotional stress. In the neurology literature, these episodes carry several names, including “painful tonic spasms” and “paroxysmal tonic seizures,” which can make it harder to track down information about them.

Isolated myoclonic jerks, sudden involuntary twitches of a single muscle group below the level of a spinal cord injury, have also been attributed to spinal cord seizure activity. In one reported case involving a man with complete cervical quadriplegia, rhythmic myoclonic movements appeared in muscles that had no voluntary connection to the brain, pointing to the spinal cord itself as the generator of the abnormal electrical discharge.²

How to Tell Them Apart from Brain-Origin Seizures

The resemblance to epileptic seizures is strong enough to fool even experienced clinicians. A limb suddenly going rigid and a person crying out in pain looks, at first glance, a lot like a focal motor seizure. There are several reliable distinguishing features, though:

• Consciousness stays intact. A person having a spinal cord seizure remains fully aware throughout the episode. There is no confusion, no post-event drowsiness (the “postictal” fog familiar after epileptic seizures), and no memory gap.
• Normal brain-wave recordings. An electroencephalogram (EEG) run during or immediately after an episode shows no epileptic discharges. Early investigators studying painful tonic spasms in multiple sclerosis confirmed that no patient had an EEG abnormality during the attack.³
• Correlation with spinal cord signs. The episodes cluster in people who already have clinical evidence of significant spinal cord disease, such as sensory loss at a defined level, Lhermitte sign (an electric-shock feeling running down the spine when the neck is flexed), or existing weakness in the limbs.³
• Trigger zones. Many patients can identify a specific patch of skin or a particular movement that reliably provokes an episode. That trigger zone closely matches the level of their spinal cord lesion, not a region of the brain.

These features together make a convincing case that the seizure generator is inside the spinal cord rather than the cortex. Still, the distinction matters practically because the workup and treatment path differ. An epilepsy-focused evaluation, repeated EEGs, brain MRIs, and standard anticonvulsant protocols, can waste months when the real problem sits in the spine.

Root Causes and Conditions That Produce Them

Spinal cord seizures are rare and have been documented across a surprisingly varied set of conditions. The common thread is damage to the spinal cord, specifically to the myelin insulation around nerve fibers or to the cord’s internal gray matter, that destabilizes normal signaling.

Multiple Sclerosis and Neuromyelitis Optica

Multiple sclerosis (MS) is the condition most closely linked with spinal cord seizures in the medical literature. Tonic spasms in MS are considered a classic, if infrequent, feature.⁴ They tend to appear when there is active demyelination in the spinal cord, and autopsy studies have confirmed extensive demyelinating plaques involving both white and gray matter in affected segments.³ Neuromyelitis optica (NMO), a related autoimmune condition that preferentially attacks the spinal cord and optic nerves, can produce a nearly identical picture. The proposed mechanism, axonal irritability from inflammatory mediators and cross-talk between partially stripped nerve fibers, applies equally in both diseases.⁵

Transverse Myelitis

Acute transverse myelitis, an inflammatory attack on a segment of spinal cord, is another well-documented trigger. The term encompasses a broad range of causes, from post-infectious immune reactions to autoimmune flares, and prognosis varies widely depending on the specific underlying etiology.⁶ Early case reports of spinal cord seizures outside of MS focused heavily on transverse myelopathy as a cause.¹

Traumatic Spinal Cord Injury

Until the early 1990s, spinal cord seizures had never been formally reported in traumatic spinal cord injury. A case involving a man with complete cervical quadriplegia changed that, demonstrating that even in the absence of any inflammatory or autoimmune process, the structural damage from trauma alone could generate seizure-like myoclonic activity below the injury level.² This expanded the recognized spectrum of causes and raised questions about how many unexplained spasms in people with spinal cord injuries might actually be spinal seizures going unrecognized.

Spinal Cord Ischemia

Reduced blood flow to the spinal cord, sometimes called a spinal stroke, is far less common than a cerebral stroke, diagnosed roughly a hundred times less often.⁷ But when it does occur, the resulting tissue damage can produce the same kind of destabilized signaling that underlies spinal cord seizures. MRI with diffusion-weighted sequences is the main tool for confirming spinal cord ischemia, and the condition remains poorly understood compared to its cerebral counterpart.

Why the Spinal Cord Can Seize at All

Most people associate seizures exclusively with the brain, and understandably so. The cortex is a dense network of interconnected neurons designed for complex signaling, and when that network misfires, the result is an epileptic seizure. The spinal cord is not wired the same way, but it does contain its own populations of interneurons and local circuits that can generate rhythmic or paroxysmal activity independently.

Two mechanisms have received the most attention. The first is ephaptic conduction, sometimes described as electrical “cross-talk.” When myelin is stripped away from neighboring nerve fibers, as happens in MS and NMO, electrical impulses can jump directly from one bare axon to another without crossing a normal synapse. This creates an abnormal chain reaction: a signal that should travel down one fiber instead spreads laterally, recruiting nearby fibers into synchronized firing. Researchers studying paroxysmal tonic spasms in MS specifically proposed this transversely spreading ephaptic activation as the mechanism behind the attacks.⁵

The second mechanism is the breakdown of inhibitory control. The spinal cord relies heavily on GABA, a chemical messenger that normally holds motor neurons in check. After spinal cord injury, the balance between excitation and inhibition shifts. Persistent ionic currents in motor neurons ramp up, while GABAergic inhibition falters. This combination leaves neurons primed to fire excessively, which may contribute to both the chronic spasticity that many spinal cord injury patients experience and, at its extreme, to outright seizure-like episodes.⁸

These two mechanisms are not mutually exclusive. In a cord damaged by inflammation, trauma, or ischemia, you can have both the loss of myelin enabling ephaptic cross-talk and the collapse of inhibitory signaling creating hyperexcitable neurons. The result is a local circuit that behaves, briefly and episodically, like a small seizure focus.

Treatment Approaches

Because spinal cord seizures are rare and have historically been lumped in with spasticity or misidentified as epilepsy, there is no large randomized trial guiding treatment. Management draws on case reports, small series, and extrapolation from animal work.

Anticonvulsant Medications

Carbamazepine is the drug most frequently reported as effective. Case reports dating back to the early 1970s described patients with “denervation hyperpathia,” a convulsive-like spinal cord syndrome, responding well to carbamazepine therapy.⁹ Its mechanism of stabilizing sodium channels aligns with the idea that the underlying problem is hyperexcitable, partially demyelinated nerve fibers firing inappropriately.

Laboratory studies using animal models of spinal seizures have tested a wider range of anticonvulsants. In one systematic evaluation using a spinal cord preparation, carbamazepine, phenytoin, diazepam, phenobarbital, and valproate all showed activity against tonic spinal seizure patterns, with diazepam requiring by far the lowest dose. The fact that these drugs worked at doses within their normal therapeutic range was considered a good sign for clinical applicability.¹⁰

Baclofen and GABA-Based Therapies

Given that the loss of GABAergic inhibition plays a role in spinal hyperexcitability, drugs that boost GABA signaling are a logical treatment choice. Baclofen, a GABA-B receptor agonist, is widely used for spinal cord injury-related spasticity, and intrathecal delivery (pumped directly into the spinal fluid) produces substantial reductions in muscle tone. Systematic reviews of intrathecal baclofen in people with chronic spinal cord injury show consistent drops in spasticity scores from severe to mild-to-moderate levels.¹¹ While the evidence is stronger for general spasticity than for discrete seizure-like episodes, the shared mechanism of motor neuron hyperexcitability makes baclofen a reasonable approach for patients whose spinal cord seizures do not respond to standard anticonvulsants.

Vagus Nerve Stimulation

One of the more intriguing findings comes from animal research. In a study using rats with induced spinal cord seizures, vagus nerve stimulation halted ongoing seizure activity in the large majority of animals. However, when the spinal cord was cut above the seizure focus, vagus nerve stimulation no longer worked, indicating that the effect depends on intact descending pathways from the brainstem to the cord.¹² This has implications for potential clinical use: vagus nerve stimulation might help patients with incomplete spinal cord injuries whose descending tracts are partly preserved, but would be unlikely to work in someone with a complete transection.

Complications from Treatment Itself

One ironic wrinkle is that baclofen, the same drug used to calm spinal cord hyperexcitability, can itself provoke seizures when delivered intrathecally. Reports have documented epileptic seizures developing in patients receiving intrathecal baclofen, though in those cases the seizures originated in the brain rather than the cord. Adding antiepileptic medication allowed those patients to continue intrathecal baclofen treatment without further seizure episodes.¹³

Baclofen also carries risk on the other end: withdrawal. Abruptly stopping either oral or intrathecal baclofen can trigger a life-threatening withdrawal syndrome featuring rebound spasticity, autonomic instability, and in severe cases, rhabdomyolysis or multi-organ failure. The risk is greater with the intrathecal route, where a pump malfunction or catheter kink can cause a sudden, unintended interruption of drug delivery.¹⁴ Patients on intrathecal baclofen pumps and their caregivers need to know the early signs of withdrawal, which include escalating spasticity, sweating, rapid heart rate, and agitation, and treat them as a medical emergency.

Why These Episodes Are Underrecognized

Spinal cord seizures sit in an awkward gap between neurology subspecialties. Epileptologists focus on the brain. Spinal cord injury specialists are steeped in managing spasticity and autonomic dysreflexia. The concept that the spinal cord can produce its own seizure-like activity does not fit neatly into either camp. As a result, these episodes tend to be attributed to “just spasms” or dismissed when EEGs come back normal.

The terminology itself contributes to the confusion. “Painful tonic spasm,” “paroxysmal tonic seizure,” “spinal myoclonus,” and “spinal cord seizure” all describe overlapping phenomena, but clinicians encountering one term may not connect it to the others. The literature on tonic spasms in MS, for instance, developed somewhat separately from the literature on myoclonic activity after traumatic spinal cord injury, even though the underlying physiology shares common threads.

For patients, the practical consequence is often a long diagnostic journey. Someone with MS who develops sudden, painful limb stiffening several times a day might first be evaluated for epilepsy, then for a movement disorder, then told the episodes are psychogenic when no brain abnormality appears on testing. Awareness that spinal cord seizures exist and that a normal EEG does not rule out a seizure originating below the brainstem can short-circuit that frustrating process considerably.

Insights from Animal Models

Much of what we know about the pharmacology of spinal cord seizures comes from laboratory models rather than human trials, simply because the condition is too rare in people for large studies. Researchers have developed spinal seizure models using cooling-induced seizure activity in isolated spinal cord preparations and strychnine-sensitized mice. The strychnine model, which reduces spinal inhibition to a point where handling alone can trigger seizures, has been useful for testing which classes of drugs act specifically at the spinal level. In that model, competitive NMDA receptor antagonists blocked seizure activity while NMDA channel blockers did not, instead producing ataxia and tremors, suggesting the two drug classes work through meaningfully different pathways at the spinal cord level.¹⁵

These models are not perfect stand-ins for the human condition, and translating dose-response data from rodent spinal cords to human clinical practice requires significant caution. But they have been valuable for screening potential drug candidates and for building a mechanistic picture of how excitatory and inhibitory systems interact at the spinal cord level during paroxysmal activity. The cooling model, for example, confirmed that conventional anticonvulsants like carbamazepine and diazepam suppress spinal seizure patterns at clinically relevant doses, lending confidence to the case-report evidence for their use in patients.¹⁰

Whether targeted NMDA-receptor-based therapies or more refined GABA-boosting strategies will eventually make it into human trials for spinal cord seizures remains an open question. The rarity of the condition makes conventional clinical trials difficult to organize, and for now, treatment decisions continue to rest on the accumulated weight of case reports, small series, and the pharmacological principles established in laboratory work.